JPM is very different from State Street. JPM has a very large prime broking unit that provides services to hedge funds which includes arranging to borrow shares from JPM's custodial business one of the largest in the world.
MSB's share price is cum sorting out short term finances. Yes, revenues will grow quickly for Ryoncil but not quick enough for the balance sheet to stay in good shape. I published my valuation for Ryoncils current FDA approval $2.60 to Mesoblast valuing the emerging commercial enterprise at A$2.981 billion. That is generous considering the hockey stick assumption on sales growth.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.035(1.88%) |
Mkt cap ! $2.331B | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.94 | $1.82 | $11.55M | 6.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40245 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |